Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope

Area of Science:

• Rheumatology
• Immunology
• Pulmonology

Background:

• Systemic sclerosis (SSc) involves fibroblast activation and excessive extracellular matrix secretion.
• Current treatments lack efficacy in modifying SSc-related fibrosis.
• There is a critical need for novel therapeutic targets in SSc management.

Purpose of the Study:

• To review the current therapeutic landscape for Systemic Sclerosis.
• To examine emerging therapeutic targets and treatments for SSc.
• To assess the efficacy of existing and novel SSc interventions.

Main Methods:

• Literature review of current treatments for Systemic Sclerosis.
• Analysis of recent clinical trial findings for SSc therapeutics.
• Examination of emerging therapeutic targets in SSc pathogenesis.

Main Results:

• Nintedanib demonstrated efficacy in slowing FVC decline in SSc-associated interstitial lung disease but not skin fibrosis.
• Cannabinoid receptor 2 agonists show promising results in Phase II trials, with Phase III anticipated.
• Numerous other targets are under investigation in ongoing clinical trials for SSc.

Conclusions:

• Nintedanib is a licensed treatment for SSc-related lung disease, yet skin fibrosis remains unaddressed.
• Emerging therapeutics targeting novel pathways offer potential for improved SSc management.
• Continued research into SSc pathogenesis is crucial for identifying future treatment strategies.